Call Us Now (800) 852-4465
Info For Physicians
About Pulmonx
Facebook-f X-twitter Linkedin-in Youtube
Zephyr By Pulmonx
Zephyr By Pulmonx
Call Us Now (800) 852-4465

References

  1. Criner, GJ, Sue, R, Wright, S, Dransfield, M, Rivas-Perez, H, Wiese, T & Morrissey, B. A multicenter randomized controlled trial of Zephyr® endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med, 2018; 198(9), 1151-1164.
  2. Emphysema. MedlinePlus. https://medlineplus.gov/emphysema.html . Published May 17, 2018. Accessed June 25, 2018.
  3. Gore et al., How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax, 2000; 55(12), 1000-1006.
  4. Gardiner C, et al., Exploring the care needs of patients with advanced COPD: An overview of the literature. Respiratory Medicine, 2010; 104(2), 159-165.
  5. Vermeire, P, The burden of chronic obstructive pulmonary disease. Respiratory Medicine, 2002; 96, S3-S10.
  6. COPD: Challenging Symptoms, Stigma and Stereotypes Patient Survey Fact Sheet. https://www.emphysema.net/Survey_Fact_Sheet.htm . Accessed Oct. 4, 2017.
  7. Kemp, SV, Slebos, DJ, Kirk, A, Kornaszewska, M, Carron, K, Ek, L & Briault, A. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med, 2017; 196(12), 1535-1543.
  8. Valipour, A, Slebos, DJ, Herth, F, Darwiche, K, Wagner, M, Ficker, JH, & Eberhardt, R. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med, 2016; 194(9), 1073-1082, and data on file at Pulmonx.
  9. Klooster, K, Hartman, JE, ten Hacken, NH, Slebos, DJ. One-year follow-up after endobronchial valve treatment in patients with emphysema without collateral ventilation treated in the STELVIO trial. Respir, 2017; 93(2), 112-121.
US-EN-1713-v1
Zephyr By Pulmonx

 Important Safety Information: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr Valve is contraindicated in patients who have not quit smoking. Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr Valve.

Caution: Federal law restricts this device to sale by or on the order of a physician.

© 2021-Present Pulmonx Corporation or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates. US-EN-405-v5

Pulmonx Makers of Zephyr Valve
Pulmonx Makers of Zephyr Valve
Zephyr By Pulmonx
Follow Us
Facebook fb X x Linkedin LinkedIn Youtube youtube
Do Not Sell or Share My Personal Information

Request a Phone Call

"*" indicates required fields

This field is hidden when viewing the form
Name*
*
This field is hidden when viewing the form
MM slash DD slash YYYY
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

How It Works

The Zephyr® Valve is not another medication or surgery. The valves are placed by bronchoscopy which requires no incisions or cutting, so the benefits are achieved without many of the risks of traditional surgical options. The minimally invasive procedure allows the healthier parts of your lungs to expand, lifts pressure off the diaphragm, and helps you breathe easier.1

Gmail Instructions

Gmail Spam Gmail Spam If you do not see an email from “Val at Zephyr Valve” in your inbox within 15 minutes of signing up, go to your “Spam” folder within Gmail. (You may have to click "More" to see the Spam folder.) Select the email from "Val at Zephyr Valve."   There will be a gray box at the top that says “Why is this message in spam?” Click the “Report Not Spam” button. This will move the email to your inbox.Gmail Not Spam   Go back to your inbox and open the email. Click on the icon next to “Val at Zephyr Valve”, you’ll see a person icon with a “+”. Click that, and you can add Val to your Contacts list. If you don’t receive a second email from us in a few days, please check your Spam folder again. Add to Contacts

Treating Physician and Assessment Center Criteria

Treating Physician Criteria
Criteria for a physician to be added to the locator: Complete Pulmonx Zephyr Valve training, which includes online, in-person and hands-on training on the Zephyr Valve procedure and related diagnostic tools, and how each fits into the patient care pathway; completion of three (3) Zephyr Valve cases; and completion of 45-Day Outcomes Review of three (3) cases with Pulmonx Medical Affairs.
Annual criteria for a physician to remain on the locator after initial inclusion: Complete a full workup for six (6) Zephyr Valve patients, up to and including the Chartis® System pulmonary assessment.
Assessment Center Criteria
Criteria of an assessment center to be added to the locator:
  • Must have access to body plethysmography.
  • Must have access to high-resolution CT.
The physicians do not pay or receive a fee for inclusion on this list. Some physicians on this list may provide consulting services to the company.
Call Us Now (800) 852-4465
Info For Physicians
About Pulmonx